We here demonstrate that the CD19-4D5scFv fusion protein redirects the CD19-specific CAR T cells towards the ErbB2+ cancer cells and activates the CAR T cells to efficiently eliminate the CD19− ErbB2+ cancer cells in vitro and in a xenograft mouse model. This evidence concerns the gene ERBB2 and cancer.